AbCellera is a Vancouver biotechnology company that discovers and develops antibody medicines using an integrated platform that combines biology, computation, and engineering. The company has worked with more than 40 partners on over 100 antibody drug programs and also advances internal pipeline assets in areas such as menopause-related vasomotor symptoms, atopic dermatitis, autoimmunity, and oncology. Its platform is designed for complex transmembrane proteins, bispecific antibodies, and antibody-drug conjugates.